Search research articles
Contact Us
Filters
Showing results (11-20 of 43) with videos related to
Page
of 5
Sort By:
Antimicrobial Agents and Chemotherapy
|
May 5, 2010
Syndecan-Fc hybrid molecule as a potent in vitro microbicidal anti-HIV-1 agent
Michael D Bobardt, Udayan Chatterji, Lana Schaffer, et al.
Plos One
|
April 23, 2016
Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175
Philippe A Gallay, Udayan Chatterji, Michael D Bobardt, et al.
The Journal of Biological Chemistry
|
October 10, 2006
Trim5alpha accelerates degradation of cytosolic capsid associated with productive HIV-1 entry
Udayan Chatterji, Michael D Bobardt, Peter Gaskill, et al.
Plos One
|
June 11, 2019
The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice
Philippe Gallay, Daren Ure, Michael Bobardt, et al.
Antimicrobial Agents and Chemotherapy
|
May 16, 2012
The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes
Sam Hopkins, Michael Bobardt, Udayan Chatterji, et al.
Nature Structural & Molecular Biology
|
December 14, 2004
Structural mapping of CD134 residues critical for interaction with feline immunodeficiency virus
Aymeric de Parseval, Udayan Chatterji, Garrett Morris, et al.
Plos One
|
February 18, 2014
HCV core residues critical for infectivity are also involved in core-NS5A complex formation
Katarzyna Gawlik, James Baugh, Udayan Chatterji, et al.
Antimicrobial Agents and Chemotherapy
|
March 21, 2012
Sublimable C5A delivery provides sustained and prolonged anti-HIV microbicidal activities
Richard Maskiewicz, Michael Bobardt, Udayan Chatterji, et al.
Plos One
|
August 12, 2015
The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action
Philippe A Gallay, Michael D Bobardt, Udayan Chatterji, et al.
Gastroenterology
|
October 12, 2014
Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production
Sandra Phillips, Shilpa Chokshi, Udayan Chatterji, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 43) with videos related to
Sort By:
Page
of 5
Antimicrobial Agents and Chemotherapy
|
May 5, 2010
Syndecan-Fc hybrid molecule as a potent in vitro microbicidal anti-HIV-1 agent
Michael D Bobardt, Udayan Chatterji, Lana Schaffer, et al.
Plos One
|
April 23, 2016
Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175
Philippe A Gallay, Udayan Chatterji, Michael D Bobardt, et al.
The Journal of Biological Chemistry
|
October 10, 2006
Trim5alpha accelerates degradation of cytosolic capsid associated with productive HIV-1 entry
Udayan Chatterji, Michael D Bobardt, Peter Gaskill, et al.
Plos One
|
June 11, 2019
The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice
Philippe Gallay, Daren Ure, Michael Bobardt, et al.
Antimicrobial Agents and Chemotherapy
|
May 16, 2012
The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes
Sam Hopkins, Michael Bobardt, Udayan Chatterji, et al.
Nature Structural & Molecular Biology
|
December 14, 2004
Structural mapping of CD134 residues critical for interaction with feline immunodeficiency virus
Aymeric de Parseval, Udayan Chatterji, Garrett Morris, et al.
Plos One
|
February 18, 2014
HCV core residues critical for infectivity are also involved in core-NS5A complex formation
Katarzyna Gawlik, James Baugh, Udayan Chatterji, et al.
Antimicrobial Agents and Chemotherapy
|
March 21, 2012
Sublimable C5A delivery provides sustained and prolonged anti-HIV microbicidal activities
Richard Maskiewicz, Michael Bobardt, Udayan Chatterji, et al.
Plos One
|
August 12, 2015
The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action
Philippe A Gallay, Michael D Bobardt, Udayan Chatterji, et al.
Gastroenterology
|
October 12, 2014
Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production
Sandra Phillips, Shilpa Chokshi, Udayan Chatterji, et al.
Page
of 5